10-Q quarterly report · filed Nov 5, 2026

Intellia Therapeutics, Inc. (NTLA) Q3 2026 10-Q Quarterly Report

Short answer

Intellia Therapeutics, Inc. (NTLA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $7M (down 48.0% year over year) with net income of −$127M.

Q3 2026 key financials · XBRL

Revenue
$7M
−48.0% YoY · −6.5% QoQ
Net income
−$127M
−25.8% YoY · −19.6% QoQ
Operating margin
-1707.7%
EPS (diluted)
−$0.92
−1.1% YoY · −15.0% QoQ

Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) Q3 2026 10-Q on SEC EDGAR. USD.

Intellia Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $7.2M, down $6.6M YoY from $13.8M
  • Operating loss $122.3M vs $111.5M YoY, net loss $127.5M vs $101.3M
  • Nex-z R&D $21.4M, highest program spend, up $1.5M; lonvo-z $10.2M, down $4.9M
  • Cash, equivalents and marketable securities $614.8M; operating cash outflow $285.9M through nine months
  • Lonvo-z BLA Priority Review, PDUFA date March 10, 2027; planned launch first quarter 2027 if approved

Risk Factors

  • Newly added risk, FDA acceptance of lonvo-z BLA and Priority Review triggered uncertainty for first in vivo CRISPR therapeutic application, with PDUFA date March 10, 2027
  • Most material update, MAGNITUDE and MAGNITUDE-2 clinical holds lifted in first quarter 2026 after Grade 4 liver injury and patient death
  • Regulatory risk, FDA may impose extended follow-up, including a recommended 15-year observation period for genome-editing recipients
  • Legal risk, PTAB again awarded CRISPR eukaryotic patent priority to Broad Institute on March 26, 2026, with UC/Vienna/Charpentier appeal pending
  • Financial risk, September 2026 credit facility permits up to $400 million but requires minimum $50 million liquidity before lonvo-z BLA approval

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Intellia Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.